MAIA Biotechnology, Inc. (MAIA): R&D Expense
$453.7K
Year ended 2025-12-31
$645.8K
Trailing 12 months to 2026-06-30
-63.0%
3-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $453.7K | -95.5% | 2026-03-23, From 2025-01-01 |
| 2024-12-31 | $10.01M | -9.9% | 2025-03-21, From 2024-01-01 |
| 2023-12-31 | $11.11M | +24.4% | 2025-03-21, From 2023-01-01 |
| 2022-12-31 | $8.93M | +155.5% | 2024-03-21, From 2022-01-01 |
| 2021-12-31 | $3.50M | n/a | 2023-03-24, From 2021-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | 2025-12-31 | $453.7K | -95.5% |
| Cocrystal Pharma, Inc. (COCP) | 2025-12-31 | $5.05M | -59.7% |
| FibroBiologics, Inc. (FBLG) | 2025-12-31 | $7.41M | +64.5% |
| Can-Fite BioPharma Ltd. (CANF) | 2025-12-31 | $6.69M | +16.3% |
| Kala Bio, Inc. (KALA) | 2025-12-31 | $18.78M | -15.0% |
| Korsana Biosciences, Inc. (KRSA) | 2025-12-31 | $959.0K | +235.3% |
| Medicus Pharma Ltd. (MDCX) | 2025-12-31 | $7.72M | +118.9% |
| Oragenics Inc (OGEN) | 2025-12-31 | $2.39M | -41.8% |
| Indaptus Therapeutics, Inc. (INDP) | 2025-12-31 | $9.34M | +28.8% |
Compare MAIA, COCP, FBLG, CANF side by side · Screen every company in Pharmaceutical Preparations ↗